- Home
- LPA vs BNTC Comparison
LPA vs BNTC Comparison
Compare LPA & BNTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPA
- BNTC
- Stock Information
- Founded
- LPA 2013
- BNTC 1995
- Country
- LPA United States
- BNTC United States
- Employees
- LPA N/A
- BNTC N/A
- Industry
- LPA
- BNTC Biotechnology: Pharmaceutical Preparations
- Sector
- LPA
- BNTC Health Care
- Exchange
- LPA Nasdaq
- BNTC Nasdaq
- Market Cap
- LPA 310.7M
- BNTC 339.8M
- IPO Year
- LPA N/A
- BNTC N/A
- Fundamental
- Price
- LPA $9.20
- BNTC $16.11
- Analyst Decision
- LPA
- BNTC Strong Buy
- Analyst Count
- LPA 0
- BNTC 7
- Target Price
- LPA N/A
- BNTC $24.43
- AVG Volume (30 Days)
- LPA 6.9K
- BNTC 37.6K
- Earning Date
- LPA 03-25-2025
- BNTC 05-12-2025
- Dividend Yield
- LPA N/A
- BNTC N/A
- EPS Growth
- LPA N/A
- BNTC N/A
- EPS
- LPA N/A
- BNTC N/A
- Revenue
- LPA $44,311,428.00
- BNTC N/A
- Revenue This Year
- LPA N/A
- BNTC N/A
- Revenue Next Year
- LPA N/A
- BNTC N/A
- P/E Ratio
- LPA N/A
- BNTC N/A
- Revenue Growth
- LPA 22.46
- BNTC N/A
- 52 Week Low
- LPA $6.00
- BNTC $4.75
- 52 Week High
- LPA $525.00
- BNTC $15.97
- Technical
- Relative Strength Index (RSI)
- LPA N/A
- BNTC 70.37
- Support Level
- LPA N/A
- BNTC $14.90
- Resistance Level
- LPA N/A
- BNTC $15.97
- Average True Range (ATR)
- LPA 0.00
- BNTC 1.03
- MACD
- LPA 0.00
- BNTC 0.32
- Stochastic Oscillator
- LPA 0.00
- BNTC 85.59
About LPA Logistic Properties of the Americas
Logistic Properties of the Americas is a fully-integrated, internally managed real estate company that develops, owns and manages a diversified portfolio of warehouse logistics assets in Central America and the South America. It focuses on modern Class A logistics real estate in high growth and high barrier-to-entry markets that are undersupplied and have low penetration rates.
About BNTC Benitec Biopharma Inc.
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.